16 Oct 2007 Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection
13 Oct 2007 WILEX' second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN
12 Oct 2007 Genmab Amends HuMax-CD4 Pivotal Study in CTCL
12 Oct 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
09 Oct 2007 MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis Research
06 Oct 2007 New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
06 Oct 2007 Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in Europe
05 Oct 2007 ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
04 Oct 2007 Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
04 Oct 2007 Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
03 Oct 2007 Roche Files CTA for Third Genmab Antibody
03 Oct 2007 Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer
02 Oct 2007 Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
01 Oct 2007 Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 AntibodyPromotes Remyelination
28 Sep 2007 Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
28 Sep 2007 Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus
27 Sep 2007 Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease
27 Sep 2007 Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
26 Sep 2007 Biotie has started the first phase I clinical trial with its fully human VAP-1 monoclonal antibody as it has received the final regulatory approval to do so
26 Sep 2007 Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasis
26 Sep 2007 New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
22 Sep 2007 Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
21 Sep 2007 FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
21 Sep 2007 ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
21 Sep 2007 Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up